Kim et al. have shown that insulin sensitizers (metformin or TZDs) were independently associated with improvements in forced vital capacity (FVC) in persons with T2D and COPD (Kim et al., 2010). The gene discussed is INS; the disease is chronic obstructive pulmonary disease.